The Basement Experiment That Became a $2 Billion Best-Seller

In a world of constant change, one thing remains steady: Americans love for chocolate. Today we focus on the ultimate “forever stock.” Backed up by more than a century of brand power, this business will remain as relevant for our children and grandchildren as it was for our parents and grandparents. Read More …

Two Important Updates on Iovance Biotherapeutics

Dear Biotech Frontiers Subscribers: We have two timely pieces of news to digest. 1. This past Friday, February 16, the Food and Drug Administration (“FDA”) granted Iovance Biotherapeutics’ (Nasdaq: IOVA) lifileucel therapy accelerated approval for advanced melanoma, making it the first and only tumor-infiltrating lymphocyte (“TIL”) treatment available for cancer. Lifileucel’s approval is an important Read More …

Action to Take: Buy Shares of MRCY

Action to Take: Buy Shares of Mercury Systems (MRCY)  On February 6, after the market closed, Mercury Systems (Nasdaq: MRCY) reported earnings for its second quarter 2024 fiscal year – for the period ending December 2023.  As is often the case with companies in a turnaround mode, the results were not good. In fact, company Read More …

Buy Alert: IOVA for Biotech Frontiers Portfolio

Dear Porter & Co. Biotech Frontiers Subscribers: One of the defining aspects of biotech is that it’s a catalyst-driven investment domain. This means that the fate of biotech investments often depends on specific, concrete events – such as clinical-trial-data releases or regulatory decisions. These decisions can drive biotech stocks much higher… or much lower.   This Read More …